Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Abstract Background Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system act...

Full description

Bibliographic Details
Main Authors: Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Naozumi Hashimoto
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Cancer
Subjects:
Distant metastases
EGFR-TKIs
EGFR mutation
Non-small cell lung cancer
Osimertinib
Online Access:https://doi.org/10.1186/s12885-022-09741-8

Internet

https://doi.org/10.1186/s12885-022-09741-8

Similar Items